OS Therapies (NYSEAMERICAN:OSTX) Upgraded to “Hold” at Zacks Research

Posted by on Jun 6th, 2026

OS Therapies (NYSEAMERICAN:OSTX – Get Free Report) was upgraded by investment analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Thursday,Zacks.com reports.

Several other equities analysts have also weighed in on the stock. Lake Street Capital cut their price objective on shares of OS Therapies from $14.00 to $13.00 and set a “buy” rating on the stock in a research report on Tuesday, May 19th. D. Boral Capital reaffirmed a “buy” rating and set a $20.00 price objective on shares of OS Therapies in a research report on Thursday, April 30th. Two investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $16.50.

Check Out Our Latest Research Report on OS Therapies

OS Therapies Price Performance

NYSEAMERICAN OSTX opened at $1.78 on Thursday. The company has a 50 day simple moving average of $1.61 and a 200-day simple moving average of $1.55. The firm has a market capitalization of $79.28 million, a price-to-earnings ratio of -1.65 and a beta of -0.95. OS Therapies has a 52-week low of $1.15 and a 52-week high of $2.57.

OS Therapies (NYSEAMERICAN:OSTX – Get Free Report) last posted its quarterly earnings results on Monday, May 18th. The company reported ($0.27) earnings per share (EPS) for the quarter. On average, analysts predict that OS Therapies will post 0.16 EPS for the current year.

Hedge Funds Weigh In On OS Therapies

Several hedge funds and other institutional investors have recently added to or reduced their stakes in OSTX. Millennium Management LLC acquired a new position in OS Therapies during the third quarter valued at approximately $183,000. Two Sigma Investments LP acquired a new stake in shares of OS Therapies in the third quarter worth $169,000. Geode Capital Management LLC grew its stake in shares of OS Therapies by 31.1% in the fourth quarter. Geode Capital Management LLC now owns 246,038 shares of the company’s stock worth $344,000 after acquiring an additional 58,350 shares during the last quarter. Virtu Financial LLC grew its stake in shares of OS Therapies by 252.0% in the third quarter. Virtu Financial LLC now owns 75,801 shares of the company’s stock worth $149,000 after acquiring an additional 54,269 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of OS Therapies in the second quarter worth $63,000.

About OS Therapies

(Get Free Report)

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

Featured Stories

Receive News & Ratings for OS Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OS Therapies and related companies with MarketBeat.com's FREE daily email newsletter.